{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Xilio Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"XLO"},"Address":{"label":"Address","value":"828 WINTER STREET,SUITE 300, WALTHAM, Massachusetts, 02451, United States"},"Phone":{"label":"Phone","value":"+1 617 430-4680"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index."},"CompanyUrl":{"label":"Company Url","value":"https://www.xiliotx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Frankenfield","title":"Chief Operating & Financial Officer"},{"name":"Katarina Luptakova","title":"Chief Medical Officer"},{"name":"Ren√© Russo","title":"President, Chief Executive Officer & Director"},{"name":"Uli Bialucha","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}